Major depressive disorder (MDD) is a leading cause of suicide in the world. Monoamine-
based antidepressant drugs are a primary line of treatment for this mental disorder, although …

Background A significant proportion of adults with major depressive disorder (MDD) do not
respond to treatments which are currently used in clinical practice such as first-generation …

Ketamine commonly and rapidly induces dissociative and other altered states of
consciousness (ASCs) in humans. However, the neural mechanisms that contribute to these …

Background Racemic ketamine is a mixture of (R)-ketamine (arketamine) and (S)-ketamine
(esketamine), with the latter regarded as the main isomer for antidepressant effects …

Abstract Lower Urinary Tract Symptoms (LUTS) are frequently present in the general
population as patients age with approximately a third of individuals experiencing LUTS …

Major depressive disorder (MDD) is a mental health disorder that can cause disability and
functional impairment that standard-of-care (SOC) antidepressant therapies (ADTs) can take …

Introduction Ketamine intravenous therapy (KIT) appears effective for treating depression in
controlled trials testing a short series of infusions. A rapidly proliferating number of clinics …

The separation distress hypothesis of depression, formulated in 2009, offered an affective
neuroscience perspective on our most common and costly mental health condition, as an …

The so-called “psychedelic renaissance” has stimulated expanded interest in several
classes of drugs that appear to possess transdiagnostic effects in the treatment of mental …

As a mental disease in modern society, depression shows an increasing occurrence, with
low cure rate and high recurrence rate. It has become the most disabling disease in the …